Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs – a systematic review

Robert Andrew Moore,1 Sheena Derry,1 Philip J. Wiffen1 & Sebastian Straube2

1Pain Research and Nuffield Division of Anaesthetics, University of Oxford, The Churchill, Oxford, UK and 2Division of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada

AIMS
It is common to advise that analgesics, and especially non-steroidal anti-inflammatory drugs (NSAIDs), be taken with food to reduce unwanted gastrointestinal adverse effects. The efficacy of single dose analgesics depends on producing high, early, plasma concentrations; food may interfere with this. This review sought evidence from single dose pharmacokinetic studies on the extent and timing of peak plasma concentrations of analgesic drugs in the fed and fasting states.

METHODS
A systematic review of comparisons of oral analgesics in fed and fasting states published to October 2014 reporting kinetic parameters of bioavailability, time to maximum plasma concentration (t_{max}), and its extent (C_{max}) was conducted. Delayed-release formulations were not included.

RESULTS
Bioavailability was not different between fasted and fed states. Food typically delayed absorption for all drugs where the fasting t_{max} was less than 4 h. For the common analgesics (aspirin, diclofenac, ibuprofen, paracetamol) fed t_{max} was 1.30 to 2.80 times longer than fasted t_{max}. C_{max} was typically reduced, with greater reduction seen with more rapid absorption (fed C_{max} only 44–85% of the fasted C_{max} for aspirin, diclofenac, ibuprofen and paracetamol).

CONCLUSION
There is evidence that high, early plasma concentrations produces better early pain relief, better overall pain relief, longer lasting pain relief and lower rates of remedication. Taking analgesics with food may make them less effective, resulting in greater population exposure. It may be time to rethink research priorities and advice to professionals, patients and the public.

Introduction
There is a consensus in worldwide recommendations that prescription and non-prescription (over-the-counter, OTC) non-steroidal anti-inflammatory drugs (NSAIDs) should be taken with food or with milk, and that this advice applies also to aspirin, and perhaps to paracetamol. For example, the NICE Clinical Knowledge Summary on NSAIDs advises ‘Avoiding taking the NSAID on an empty stomach’ and to ‘Take aspirin after food (to reduce the risk of gastrointestinal adverse effects)’, though it does not give this advice for paracetamol [1]. The UK National Health Service NHS Choices website advises that ‘There are no known interactions between NSAIDs and food. Ideally, take NSAIDs after eating and avoid taking them on an empty stomach. This will help minimize the risk of the medicine upsetting your stomach’ [2]. German guidelines for family physicians advise that in elderly patients NSAIDs should be taken with food and never on an empty stomach [3]. A consumer's guide on arthritis medications endorsed by...
the Canadian Rheumatology Association suggests that ‘Taking your NSAIDs with food may help to reduce stomach upset’ [4]. A number of Australian and New Zealand sources echo this general advice, and it appears to be almost universal advice, whatever the circumstance.

The theoretical rationale for taking analgesics with food is clearly to reduce or prevent adverse events. It is unclear whether this means common but mild and reversible adverse events like dyspepsia, or rare but serious adverse events like upper or lower gastrointestinal bleeding. The evidence that taking oral analgesics with food actually accomplishes this desired effect is non-existent. In single dose studies, only aspirin of the commonly used non-opioid analgesics is associated with any increased adverse event reporting over placebo (number needed to harm 44, 95% CI 23, 345) [5]. Rainsford & Bjarnason found no evidence of benefit from taking NSAIDs with food [6]. They suggested that it would be more appropriate to take OTC NSAIDs on an empty stomach because rapid onset of action is beneficial.

More rapid absorption of ibuprofen produces earlier and higher maximum plasma concentrations, producing earlier onset of analgesia combined with better overall and longer lasting analgesia in dental pain models [7–9]. The effect of fast acting formulations was pronounced, with 200 mg of a fast acting formulation producing the same or better analgesia as 400 mg ibuprofen acid, and with a reduced requirement for additional analgesic use [8].

An understanding of the effects of food on the pharmacokinetics of analgesics has therefore become a priority, particularly its effect on occasional use of OTC drugs. We have therefore conducted a systematic review of studies reporting kinetic results of oral analgesics in the fasted and fed states in humans. We considered any formulation where the drug was immediately available for absorption following ingestion, but excluded those specifically formulated for delayed or controlled release.

**Methods**

There is no published protocol for this review. Two authors independently carried out searches for potentially relevant studies, assessed studies for inclusion and extracted data using a piloted spreadsheet. Any disagreements were settled by discussion with a third author.

We used a number of methods to search for comparisons of oral analgesics in the fed and fasted states to 31 October 2014. We searched PubMed using a series of free text terms: ‘fed AND fasted AND analgesic’, and ‘fed AND fasted AND drug name’, using ‘food’, ‘meal’ or ‘milk’ as alternatives to fed. We also examined reviews for aspirin, paracetamol, and individual NSAIDs where they mentioned pharmacokinetic results, and the reference lists of any retrieved studies. For each identified study we used the ‘related citations’ function of PubMed to identify reports citing the trial in case the citing reference was also a study reporting on oral analgesics used in the fed and fasted state. Finally, we entered each included trial into Google Scholar and used the citations function to identify reports that cited the trials. Methods like this have been used with good effect to identify non-randomized studies where electronic searching is insensitive [10, 11]. We also searched Clinicaltrials.gov to identify completed or ongoing studies.

To be included, studies were required to have data on kinetic parameters in the fasted and fed state for single doses of aspirin, dipyrone, paracetamol, or any NSAID, or for a principal metabolite in blood following oral administration in humans. There was no restriction by date or language of publication. We accepted any definition of fed, meal or milk. We accepted any formulation other than delayed release formulations. Fast-acting formulations of ibuprofen were analyzed separately from ibuprofen acid, and diclofenac potassium separately from diclofenac sodium.

From each study we noted the study design (whether it was a randomized, crossover design, for example), the number and demographics of the individuals involved in the testing, the duration of fasting, the components of the meals used, the time of drug administration in relation to the meal, and the dose and formulation of the analgesic drug. The kinetic parameters noted were bioavailability (using the longest duration provided), the maximum plasma concentration (C_max) and the time at which C_max occurred (t_max).

No statistical analyses were planned. Drug concentrations were converted to mg l⁻¹ and area under the plasma concentration–time curve (AUC) to mg l⁻¹ h. We calculated a mean t_max for individual drugs weighted by the number of participants in each study. For C_max we calculated a dose-related mean, weighted by the number of participants in each study, with units of mg l⁻¹ mg⁻¹ dose. All calculations were carried out by one author and checked by another.

We wanted to compare bioavailability (AUC), t_max and C_max in the fed and fasted state.

**Results**

**Studies identified**

Searches identified 63 publications which were obtained and read. Twenty-five were excluded because they collected urine samples only, were reviews without relevant data, investigated delayed release preparations, had no fasting or fed results, or were duplicate publications (Figure 1). Six potentially relevant studies identified in clinicaltrials.gov did not provide any results and could not be used (Supplementary Table 1). We included 38 publications [12–49] with 656 unique individuals, reporting 46 fed/fasted comparisons involving 874
participants in the comparisons. Papers were published between 1972 and 2012. Because of the crossover nature of many of the studies, the number in the comparisons is more than the number of individuals. Included studies measured the pharmacokinetics of aspirin, dipyrone, paracetamol and 16 different NSAIDs. Fast acting formulations were represented by diclofenac potassium (four studies, the only diclofenac formulation with data), ibuprofen lysine (two studies), naproxen sodium (one study) and paracetamol with bicarbonate (one study).

Details of the comparisons are given in Supplementary Table 2. Of the 46 comparisons, 33 had a randomized crossover design, 12 had a crossover design but did not mention randomization and one was opportunistic. Study participants were predominantly healthy volunteers generally aged 18–50 years (20 comparisons were male only, 22 were mixed male and female), three studies were in adult patients (post-operative, inpatients, sciatica), and one was in children with cancer. The duration of fasting was typically overnight, usually with a minimum of 10 h before ingesting the test medication. Fasting patients were sometimes given a light meal about 4 h after ingestion. Analgesics were taken with these meals or a few minutes after the meal.

The types of meal were variously described (Supplementary Table 2). Twenty-eight comparisons gave details of the meals for volunteers in the fed part of the studies. These typically consisted of tea or coffee, bread or toast with jam, and often with cheese, eggs or bacon. Other meals were described only as standardized.

Table 1
Mean results by drug, weighted by number of participants in pooled analyses

| Drug                                      | Number of Comparison | Number of Participant Fasted | Mean $t_{max}$ (h) (weighted by n) | Mean $C_{max}$ (mg l$^{-1}$ mg$^{-1}$ dose) (weighted by n) | Fed/Fasting (%) |
|-------------------------------------------|----------------------|-------------------------------|-----------------------------------|------------------------------------------------------------|-----------------|
| Aspirin (as salicylic acid)               | 3                    | 30                            | 1.74 2.65 152                     | 0.093 0.079 85                                             |                 |
| Bromfenac                                 | 1                    | 68                            | 0.80 2.40 300                     | 0.078 0.022 28                                             |                 |
| Celecoxib                                 | 2                    | 51                            | 2.72 3.19 117                     | 0.0041 0.0065 159                                          |                 |
| Diclofenac potassium                      | 4                    | 115                           | 0.52 1.45 280                     | 0.041 0.022 54                                             |                 |
| Diclofenac sodium                         | 3                    | 22                            | 1.83 5.12 280                     | 0.025 0.011 44                                             |                 |
| Diflunisal                                 | 1                    | 12                            | 2.42 3.10 128                     | 0.144 0.120 83                                             |                 |
| Dipyrone (as methylaminoantipyrine)       | 1                    | 18                            | 1.50 1.90 127                     | 0.010 0.0097 97                                             |                 |
| Etoricoxib                                | 1                    | 12                            | 1.00 3.00 300                     | 0.020 0.013 65                                             |                 |
| Ibuprofen acid                            | 6                    | 109                           | 1.34 1.96 147                     | 0.076 0.059 78                                             |                 |
| Ibuprofen fast-acting                     | 2                    | 43                            | 0.71 1.44 203                     | 0.096 0.070 73                                             |                 |
| Indomethacin                              | 3                    | 86                            | 1.60 2.95 184                     | 0.065 0.030 46                                             |                 |
| Ketoprofen                                | 2                    | 24                            | 1.89 4.76 252                     | 0.153 0.094 61                                             |                 |
| Meloxicam                                 | 2                    | 22                            | 9.30 7.10 76                      | 0.059 0.068 115                                            |                 |
| Nabumetone (as 6-methoxy-2-naphthlacetic acid) | 1                | 12                            | 3.00 4.00 133                     | 0.023 0.036 157                                            |                 |
| Naproxen                                  | 2                    | 24                            | 1.90 1.93 102                     | 0.146 0.136 93                                             |                 |
| Naproxen sodium                           | 1                    | 24                            | 1.30 3.20 246                     | 0.291 0.229 79                                             |                 |
| Paracetamol                               | 4                    | 77                            | 1.58 2.08 132                     | 0.019 0.011 58                                             |                 |
| Paracetamol + bicarbonate                 | 1                    | 28                            | 0.42 0.75 179                     | 0.024 0.013 54                                             |                 |
| Surprofen                                 | 1                    | 24                            | 0.92 1.56 170                     | 0.095 0.042 44                                             |                 |
| Tenidap                                   | 1                    | 21                            | 2.90 4.40 152                     | 0.150 0.153 102                                            |                 |
| Tenoxicam                                 | 2                    | 18                            | 1.63 5.23 320                     | 0.143 0.118 83                                             |                 |
| Timegadine                                | 1                    | 10                            | 3.00 2.40 80                      | 0.0013 0.0028 215                                           |                 |
without details (12), as high fat (4), or had some other description (2).

Drug analysis was for the parent compound except for:

- aspirin, for which salicylic acid concentrations were also reported, and used;
- dipyrene, where methylaminantipyrine, the first metabolite of dipyrene which is enzymatically hydrolyzed in the intestine was measured;
- nabumetone, where 6-methoxy-2-naphthalacetic acid was measured.

**Effects of food on bioavailability**

There was no difference in bioavailability between fasting and fed states as measured by the area under the concentration–time curve (Figure 2).

**Effects of food on t_{max}**

Food typically delayed absorption for all drugs with a fasting t_{max} of under 4 h (Figure 3, Table 1). The degree of delay varied between drugs, from little or no delay in absorption for celecoxib, diflunisal, dipyrene, meloxicam and timegadine, to an increase of fed t_{max} over fasted t_{max} of 250% or more for bromfenac, diclofenac, etoricoxib, ketoprofen and tenoxicam. Ibuprofen, paracetamol and naproxen were intermediate between these extremes (Table 1).

**Effects of food on C_{max}**

Food reduced the C_{max} for all drugs with a fasting t_{max} of under 2 h (Table 1). The greatest degree of reduction in C_{max} was in analgesics with the shortest fasting t_{max} with reductions by about 50% or more for bromfenac, dexketoprofen, diclofenac, indomethacin, paracetamol and surprofen. For celecoxib, nabumetone and timegadine C_{max} increased in the fed state, while meloxicam was unaffected.

**Discussion**

The results of the review are clear. Taking analgesics with food does not affect the overall bioavailability, but for many drugs food substantially prolongs absorption and t_{max}, while substantially reducing C_{max}. This is particularly the case for those drugs whose fasting t_{max} is below 2 h, which includes analgesics typically available without prescription in many parts of the world, namely aspirin, diclofenac potassium, ibuprofen (as acid and salt) and paracetamol (Figure 4). Naproxen is affected to a much lesser extent.

The strength of these findings is that the systematic review covered all simple analgesics and NSAIDs, using a search strategy likely to be comprehensive, and which was unrestricted by date or language of publication. Included studies covered a 40 year period from 1972 to 2012. The effects of food on delayed t_{max} appeared to be similar in all the drugs examined with a fasting t_{max} of 4 h or less. The effects of food on reduced C_{max} appeared to be similar in all the drugs examined with a fasting t_{max} of less than 2 h. Results were not compromised by the inclusion of delayed or controlled formulations specifically designed to delay absorption.
There are several potential weaknesses. This review covers only a part of the potentially available data, since many bioavailability studies have been performed for regulatory or other purposes, but not published. We are aware that this may be the case from discussions with pharmaceutical companies. Effects of food are often explored to demonstrate bioavailability equivalence following small changes in formulation. This review shows that bioavailability was unaffected by food (Figure 2), and the results of such studies would therefore have been seen as unremarkable and not worthy of publication. Effects on $C_{\text{max}}$ and $t_{\text{max}}$ would probably have been overlooked as having no importance. Recent research has shown that $C_{\text{max}}$ and $t_{\text{max}}$ are more important than bioavailability, and this study may provoke companies with unpublished studies to revisit them, with a view to confirming the results presented here. We do not consider lack of publication of the reports to be a form of publication bias, since there were no grounds for bias at the time.

Other weaknesses include the small size of many of the individual studies, so some imprecision in the estimates of the magnitude of food effects is therefore likely. There were also insufficient details to determine whether the type of meal had any major consequences for any particular drug, or for drugs in general, and to explore links between physicochemical properties of individual drugs, type of meal and the effects of food. Finally, these data, while relevant to occasional use of analgesics, for headache, for example, cannot necessarily be extrapolated to long term repeat dosing.

The implications of the results are significant, and stem from the increasing understanding of the importance of early, high, plasma drug concentrations for pain relief, particularly in the treatment of acute pain. An analysis of a randomized trial in acute pain demonstrated a direct link between the concentration of ibuprofen and the absence of patients with moderate or severe pain at 1 h after dosing [7]. There was also a direct link between dose, plasma ibuprofen concentration and the changes in Western Ontario and McMaster Universities Osteoarthritis Index and visual analogue scale pain scores between baseline and after 7 days of treatment in osteoarthritis [50, 51], with a weak correlation in rheumatoid arthritis [52].

Moreover, two recent patient level analyses of data from different acute pain studies have demonstrated that speed of onset of analgesia is an important determinant of good and possibly long lasting pain relief [8, 9]. For fast-acting ibuprofen formulations with a median $t_{\text{max}}$ of 30–40 min, 200 mg provided the same pain relief after third molar extraction (number needed to treat [NNT] for at least 50% maximum pain relief over 6 h 2.9, 95% confidence interval (CI) 2.3, 4.1) as 400 mg ibuprofen.
acid with a median $t_{\text{max}}$ of 100 min (NNT 2.7, 95% CI 2.5, 3.1) in a Cochrane review [53] and in an updated analysis [8]. Poor analgesia leads to more frequent recourse to additional analgesic consumption [8, 9].

At least for ibuprofen, where we have most information, early, high plasma concentrations produce better analgesia in acute pain, and result in reduced need for remedication (Figure 5). There is no obvious reason why this should not be the case for other analgesics. If taking analgesics with food delays absorption and reduces peak plasma concentrations, poorer analgesia is likely to result. This indeed is what happened in the only test of taking food with analgesics we could find, with bromfenac [22], though the effects of food on paracetamol and naproxen were minimal. The impact on efficacy of taking analgesics with food is largely unexplored in acute and chronic pain, and this makes the case for new studies examining the effects of food on analgesic effects, as well as pharmacokinetics.

The advice to take aspirin and NSAIDs with food stems from a desire to protect people from gastrointestinal adverse events; common events like dyspepsia, and rare, serious events like gastrointestinal bleeding. Aspirin is associated with increased rates of adverse events and gastric irritation [54], but there is no evidence that taking occasional doses of NSAIDs or most other analgesics produces higher adverse event rates than placebo [5]. Nor is there any convincing evidence that food prevents any other adverse events [6].

Conclusion

This leaves us with a conundrum. Current advice to take aspirin and NSAIDs with food stems from a desire to protect people from gastrointestinal adverse events; common events like dyspepsia, and rare, serious events like gastrointestinal bleeding. Aspirin is associated with increased rates of adverse events and gastric irritation [54], but there is no evidence that taking occasional doses of NSAIDs or most other analgesics produces higher adverse event rates than placebo [5]. Nor is there any convincing evidence that food prevents any other adverse events [6].

Competing Interests

All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author). The work was supported by an investigator-initiated unrestricted educational grant from Reckitt Benckiser. Reckitt Benckiser had no role in the study design, data collection analysis and interpretation, or writing of the paper. RAM is the owner of Oxford Medical Knowledge (OMK), which received the unrestricted educational grant from Reckitt Benckiser. Dr Moore reports grants from Reckitt Benckiser, during the conduct of the study, personal fees from Reckitt Benckiser, personal fees from Novartis, grants and personal fees from Grunenthal, personal fees from Orion Pharma, personal fees from Futura Pharma, personal fees from Astellas, personal fees from Eli Lilly, personal fees from Pfizer and personal fees from Menarini, outside the submitted work. Ms Derry has nothing to disclose. Professor Wiffen has nothing to disclose. Dr Straube reports personal fees from Oxford Medical Knowledge, outside the submitted work.

The Oxford Pain Relief Trust provided institutional support for this review. We are grateful to various library services for helping us obtain copies of papers from some rather difficult to find journals.

REFERENCES

1 Clinical Knowledge Summary. Analgesia – mild to moderate pain. Available at http://cks.nice.org.uk/analgesia-mild-to-moderate-pain#topicsummary (last accessed 1 December 2014).
2 NHS Choices. Available at http://www.nhs.uk/Conditions/Anti-inflammatories-non-steroidal/Pages/Interactions-othermedicines.aspx (last accessed 1 December 2014).
3 Schubert I, Fessler J, eds. Hausärztliche Leitlinien: herausgeben von der Leitliniengruppe Hessen und der PMV forschungsgruppe. Deutscher: Ärzte-Verlag, 2009.
4 Arthritis Medications: a consumer’s guide. Available at http://www.arthritis.ca/document.doc?id=341 (last accessed 1 December 2014).
5 Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev 2011; 9: CD008659.
6 Rainsford KD, Bjaranson I. NSAIDs: take with food or after fasting? J Pharm Pharmacol 2012; 64: 65–9.
7 Laska EM, Sunshine A, Marrero I, Olson N, Siegel C, McCormick N. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther 1986; 40: 1–7.
8 Moore RA, Derry S, Straube S, Ireson-Paine J, Wiffen PJ. Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain. Pain 2014; 155: 1420–7.
9 Moore RA, Derry S, Straube S, Ireson-Paine J, Wiffen PJ. Validating speed of onset as a key component of good analgesic response in acute pain. Eur J Pain 2014 May 22. doi: 10.1002/ejp.536. [Epub ahead of print].
10 Lemeshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA. Searching one or two databases was insufficient for meta-analysis of observational studies. J Clin Epidemiol 2005; 58: 58867–73.
11 Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anesthesiology 2006; 105: 394–9.

12 Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, Dynder AL, Mazina KE, Lasserter KC, Hunt TL, Schwartz JJ, McCrea JB, Gottesdiener KM. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003; 43: 268–76.

13 Bannwarth B, Lapicque F, Netter P, Monot C, Tamisier JN, Thomas P, Royer RJ. The effect of food on the systemic availability of ketoprofen. Eur J Clin Pharmacol 1988; 33: 643–5.

14 Bogentoft C, Carlsson I, Ekenved G, Magnusson A. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur J Clin Pharmacol 1978; 14: 351–5.

15 Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions 1991; 32: 52–3.

16 Caille G, du Souich P, Besner JG, Gervais P, Vézina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med 1989; 86: 38–44.

17 Chaikin P, Marriott TB, Simon D, Weintraub HS. Comparative bioavailability of suprofen after coadministration with food or milk. J Clin Pharmacol 1988; 28: 1132–5.

18 Coates PE, Mesure R. Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. Br J Clin Pharmacol 1995; 39 (Suppl 1): 175–9.

19 Day RO, Lam S, Paull P, Wade D. Effect of food and various antacids on the absorption of tenoxicam. Br J Clin Pharmacol 1987; 24: 323–8.

20 Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C. Indomethacin serum concentrations in man. Effects of dosages, food, and antacid. Ann Rheum Dis 1976; 35: 333–8.

21 Flusser D, Zylber-Katz E, Granit L, Levy M. Influence of food on the pharmacokinetics of dipyrene. Eur J Clin Pharmacol 1988; 34: 105–7.

22 Forbes JA, Sandberg RA, Bood-Björklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy 1998; 18: 492–503.

23 Francis RJ, Dixon JS, Lowe JR, Harris PA. The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. Eur J Drug Metab Pharmacokin 1985; 10: 309–14.

24 Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K. Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol 1989; 27: 324–8.

25 George S, Dauwe K, McBurney A, Ward J. The influence of food intake on the bioavailability of timegadine, a novel non-steroidal anti-inflammatory drug. Br J Clin Pharmacol 1983; 15: 495–8.

26 Hasan SM, Ahmed T, Talib N, Hasan F. Pharmacokinetics of diclofenac sodium in normal man. Pak J Pharm Sci 2005; 18: 18–24.

27 Kapil R, Nolting A, Roy P, Fiske W, Benedek I, Abramowitz W. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Clin Ther 2004; 26: 2015–25.

28 Klueglich M, Ring A, Scheuerer S, Trommehausen D, Schuitt C, Liepold B, Berndl G. Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol 2005; 45: 1055–61.

29 Koch PA, Schultz CA, Wills RJ, Hallquist SL, Welling PG. Influence of food and fluid ingestion on aspirin bioavailability. J Pharm Sci 1978; 67: 1533–5.

30 Lafontaine D, Mailhot C, Vermeulen M, Bissonnette B, Lambert C. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm 1990 9: 773–7.

31 Levine MA, Walker SE, Paton TW. The effect of food or sucralfate on the bioavailability of S(+) and R(-) enantiomers of ibuprofen. J Clin Pharmacol 1992; 32: 1110–4.

32 Manvelian G, Daniels S, Altman R. A phase I study evaluating the pharmacokinetic profile of a novel, proprietary nano-formulated, lower-dose oral indomethacin. Postgrad Med 2012; 124: 197–205.

33 Marzo A, Dal Bo L, Wool C, Cerutti R. Bioavailability, food effect and tolerability of S-naproxen betaine sodium salt monohydrate in steady state. Arzneimittelforschung 1998; 48: 935–40.

34 McEwen J, De Luca M, Casini A, Gich I, Barbanoj MJ, Tost D, Artigas R, Mauleón D. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol 1998; 38(12 Suppl): 41S.

35 Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001; 297: 638–45.

36 Poli A, Moreno RA, Ribeiro W, Dias HB, Moreno H Jr, Muscara MN, De Nucci G. Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. Int J Clin Pharmacol Ther 1996; 34: 76–9.

37 Rostami-Hodjegan A, Shiran MR, Ayesh R, Grattan TJ, Burnett I, Darby-Dowman A, Tucker GT. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. I. A four-way crossover study to compare the concentration-time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. Drug Dev Ind Pharm 2002; 28: 523–31.
38 Runkel RA, Kraft KS, Boost G, Sevelius H, Forchielli E, Hill R, Magoun R, Szakacs JB, Segre E. Naproxen oral absorption characteristics. Chem Pharm Bull (Tokyo) 1972; 20: 1457–66.

39 Scallion R, Moore KA. Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. Clin Ther 2009; 31: 2233–41.

40 Scheidel B, Blume H, Walter K, Stanislaus F, Babej-Dölle RM. [The bioavailability of enteric coated diclofenac formulations. 2. Bioavailability following single administration of a multiple-unit formulation in comparison to a single-unit formulation under fasting and non-fasting conditions]. [Article in German]. Arzneimittelforschung 1994; 44: 544–50.

41 Siemon D, de Vries JX, Stötzer F, Walter-Sack I, Dietl R. Fasting and postprandial disposition of R(-)- and S(+) - ibuprofen following oral administration of racemic drug in healthy individuals. Eur J Med Res 1997; 2: 215–9.

42 Stempak D, Gammon J, Halton J, Champagne M, Koren G, Baruchel S. Modulation of celecoxib pharmacokinetics by food in pediatric patients. Clin Pharmacol Ther 2005; 77: 226–8.

43 Stillings M, Havlik I, Chetty M, Clinton C, Schall R, Moodley I, Muir N, Little S. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr Med Res Opin 2000; 16: 115–24.

44 Tanner T, Asley S, Munn A, Thomas T. The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. BMC Clin Pharmacol 2010; 10: 10.

45 Terhaag B, Gramatte T, Hrdlcka P, Richter K, Feller K. The influence of food on the absorption of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol 1991; 29: 418–21.

46 Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntinx AP, Meisinger MA, Huber PB, Hall TL, Yeh KC. Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Clin Pharmacol Ther 1981; 30: 385–9.

47 Türck D, Busch U, Heinzel G, Narjes H, Nemhiz G. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995; 9: 270–6.

48 Vidon N, Pfeiffer A, Godbillon J, Rongier M, Gauron S, Hirtz J, Bernier JJ, Dubois JP. Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application to diclofenac. Br J Clin Pharmacol 1989; 28: 121–4.

49 von Schrader HW, Buscher G, Dierdorf D, Mügge H, Wolf D. Nabumetone - a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Toxicol 1983; 21: 311–21.

50 Gallelli L, Galasso O, Urzino A, Saccà S, Falcone D, Palleria C, Longo P, Corigliano A, Terracciano R, Savino R, Gasparini G, De Sarro G, Southworth SR. Characteristics and clinical implications of the pharmacokinetic profile of ibuprofen in patients with knee osteoarthritis. Clin Drug Investig 2012; 32: 827–33.

51 Bradley JD, Rudy AC, Katz BP, Ryan SI, Kalasinski LA, Brater DC, Hall SD, Brandt KD. Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. J Rheumatol 1992; 19: 130–4.

52 Grennan DM, Aarons L, Siddiqui M, Richards M, Thompson R, Higham C. Dose–response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol 1983; 15: 311–6.

53 Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; 3: CD001548.

54 Edwards JE, Oldman AD, Smith LA, Carroll D, Wiffen PJ, McQuay HJ, Moore RA. Oral aspirin in postoperative pain: a quantitative systematic review. Pain 1999; 81: 289–97.

55 Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

Table S1
Details of potentially useful studies without results

Table S2
Details of individual studies